Details : The partnership between leading drug discovery start-up and leading cancer hospital paves way for the development of novel Immuno-oncology drugs that can be effective in wider patient populations.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 18, 2022
Details : Under the terms of the agreement, Olema and Aurigene will jointly direct preclinical work and, if successful, Olema will lead clinical development as well as regulatory and commercial activities.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $8.0 million
September 06, 2022
Excelra Partners with HotSpot Therapeutics to Enhance Allosteric Drug Discovery Efforts
Details : HotSpot Therapeutics plans to deploy data from Excelra’s flagship product GOSTAR toward select protein targets to augment its allosteric inhibitor candidate pipeline.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 25, 2022
Details : Under the terms of the collaboration agreement, Aurigene will lead drug discovery and pre-clinical development efforts, and EQRx will assume responsibility for clinical development, manufacturing, regulatory and commercialization efforts.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 07, 2022
Syngene International extends Long Term Research Collaboration with Bristol Myers Squibb until 2030
Details : The collaboration has been extended through the end of 2030 and will expand the breadth of drug discovery research conducted, including chemistry, biology, drug metabolism and pharmacokinetics, as well as translational medicine research and pharmaceutica...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 26, 2021